May 28, 2020

ALEXANDRIA, Va. — In a small, phase II study of a very rare cancer that develops inside a woman’s uterus during or after pregnancy, treatment with avelumab (Bavencio) potentially cured 8 out of 15 women with cancer that was resistant to single-agent chemotherapy. This is the first trial exploring use of immunotherapy in patients with gestational trophoblastic tumors (GTT) and suggests that avelumab may be a new therapeutic option for these patients. The results will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. 

May 28, 2020

ALEXANDRIA, Va. — Treatment with avelumab combined with best supportive care following chemotherapy significantly extended overall survival compared with best supportive care alone in patients with advanced urothelial cancer in the JAVELIN Bladder 100 trial. The results of this study will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 28, 2020

EGFR) mutation significantly improved disease-free survival in a phase III study. Of patients with stage II-IIIA NSCLC who received osimertinib, 90% were alive at two years without the cancer recurring, compared with 44% who received a placebo. In stage II-IIIA patients, the risk of disease recurrence or death was reduced by 83% for patients treated with adjuvant osimertinib after surgery compared to placebo.

May 28, 2020

ALEXANDRIA, Va. — Front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival vs chemotherapy in patients with a type of advanced colorectal cancer that has a high number of mutations, which previous research suggests may have a poor prognosis for some patients. This is the first time pembrolizumab has been shown to benefit these patients when used as a front-line therapy. The findings come from an interim analysis of the phase III KEYNOTE-177 trial that will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 28, 2020

ALEXANDRIA, Va. — In patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death, according to an analysis of 928 patients. COVID-19 treatment with both hydroxychloroquine and azithromycin was also strongly associated with increased risk of death, according to data from the COVID-19 and Cancer Consortium (CCC19) registry. The registry contains data from patients who have tested positive for COVID-19 and around 40% of patients in the registry also have active cancer. The data will be presented as part of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. 

 

 

May 28, 2020

ALEXANDRIA, Va. — Among patients with lung and other thoracic cancers also diagnosed with COVID-19, prior use of chemotherapy — alone or in combination with other treatments — was associated with increased risk of death, according to an analysis to be presented as part of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. The data come from the Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT) registry and are the most recent available. 

May 19, 2020

ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemicwhich provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and healthcare staff before resuming more routine care operations during the COVID-19 public health crisis.
 

May 13, 2020

ALEXANDRIA, Va. — States that adopted Medicaid expansion following passage of the Affordable Care Act (ACA) of 2010 saw greater decreases in cancer mortality rates than states that did not, according to the first nationwide study of its kind. 

May 13, 2020

ALEXANDRIA, Va. — People who quit smoking at any time — even less than 2 years before a lung cancer diagnosis — improve their chances of survival after being diagnosed with the disease, according to the results of a large international study that will be presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. 

May 13, 2020

ALEXANDRIA, Va. — Maintenance therapy with olaparib (Lynparza) extended overall survival by nearly 13 months (12.9) compared with placebo in women with platinum-sensitive relapsed ovarian cancer with BRCA 1 or 2 mutations, in a randomized phase III trial.

May 13, 2020

ALEXANDRIA, Va. — Older people with cancer set to receive anti-cancer therapy had significant improvements in quality of life when comprehensive geriatric assessment and geriatrician-led management was integrated into their care plan. The prospective, randomized, open-label INTEGERATE trial, according to the study authors, is the first randomized clinical trial in geriatric oncology to show that an integrated approach involving geriatricians and oncologists working in partnership helped improve quality of life, and reduced hospital admissions and early discontinuation of treatment due to adverse events.  

 

May 13, 2020

ALEXANDRIA, Va. — A videoconferencing intervention significantly reduced levels of anxiety and distress among “distance caregivers" who live more than an hour away from the patients with cancer they support, according to the results of a federally funded study.  

May 12, 2020

ALEXANDRIA, Va. -- Twenty-seven practices elevated their standard of care and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. The Association for Clinical Oncology (Association) commends these practices that have demonstrated their commitment to providing the highest-quality oncology care to their patients, communities, and contemporaries.

April 29, 2020

ALEXANDRIA, Va. – This year the American Society of Clinical Oncology (ASCO) will deliver the latest cancer science to the global oncology community in a new virtual format. Advances in immunotherapies and targeted therapies for lung, colorectal, ovarian, and bladder cancers; improvements in  access to cancer care, as well as the impact of COVID-19 on people with cancer are among the topics that will be highlighted in the virtual scientific program of the 2020 ASCO Annual Meeting.

April 23, 2020

ALEXANDRIA, Va. – Researchers, patient advocates, and global oncology leaders who have worked to transform cancer care around the world are among the recipients of the American Society of Clinical Oncology’s (ASCO) Special Awards – the Society’s highest honors - and Conquer Cancer, the ASCO Foundation Women Who Conquer Cancer Mentorship Awards.  

Pages